Idelalisib API is a pharmaceutical-grade phosphoinositide 3-kinase delta (PI3Kδ) inhibitor used in the treatment of chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL). It selectively inhibits the PI3Kδ signaling pathway, suppressing the proliferation and survival of malignant B lymphocytes while promoting apoptosis.
Idelalisib is formulated into oral tablet dosage forms and is widely used in targeted therapies for hematologic malignancies, particularly in patients with relapsed or refractory disease.
Manufactured under WHO-GMP-certified facilities, our Idelalisib API offers exceptional purity, stability, and batch-to-batch consistency. Every batch undergoes stringent quality testing and is supplied with comprehensive regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), Technical Data Sheet (TDS), and Product Specifications.
Idelalisib API is used in pharmaceutical formulations for the treatment of chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and small lymphocytic lymphoma (SLL).
Idelalisib selectively inhibits the PI3K delta enzyme, blocking signaling pathways essential for the growth, survival, and proliferation of malignant B cells.
Yes. We provide CoA, MSDS, Technical Data Sheet (TDS), Product Specifications, and complete regulatory documentation.
Yes. We supply Idelalisib API in commercial quantities with worldwide export support.
Get Bulk Quote via WhatsApp